Boustead Securities Client, Nano-C, Inc., Announces Signed Letter of Intent with Unify Pharmaceuticals to Pursue Strategic Partnership for Parkinson’s and COVID-19 Indications
Nano-C’s Unique Chemistry is a Key Enabler for Potential Drug Efficacy
in Broad Range of Treatments
Boustead Securities, LLC (“Boustead”) client, Nano-C, Inc. (“Nano-C” or the “Company”), a leading producer of patented specialty active ingredients and formulations, announces a signed Letter of Intent (LOI) to pursue a strategic partnership with Unify Pharmaceuticals, a Vanderbilt University spinout co-founded by Dr. Laura Dugan (Vanderbilt, Washington University, Stanford, MIT). Unify is set to begin Phase 1 clinical trials this year for drug therapies for neurodegenerative disease as well as fast-track clinical trials for treatment of COVID-19.
Nano-C and Unify have had a growing and active business relationship for several years and are pleased to formalize their strategic partnership. As Unify’s chemistry partner, Nano-C will manage the scale up and synthesis of a functionalized fullerene identified as UP-1007, Unify’s active pharmaceutical ingredient (API), at an exacting cGMP standard. Nano-C and Unify intend to execute a Contract Manufacturing and Supply Agreement covering the preparation for and completion of Phase I and fast-track clinical trials.
Dr. Dugan has studied the therapeutic properties of functionalized fullerenes for over 20 years and has published numerous scientific papers on the potential benefits of these unique APIs on neurodegenerative disease including Parkinson’s and Alzheimer’s. Pre-clinical trials showed marked efficacy on primates afflicted with Parkinson’s Disease, with statistically significant differences appearing after just 30 days vs the control with no toxicity over the course of the trial. Data from Dr. Dugan’s research is being leveraged for a possible COVID-19 drug therapy.
Fullerenes are small molecules that can be customized for use in a wide range of therapeutic applications. Their versatility stems from their fundamental molecular properties and by applying functional chemistry to their surface, they become a true molecular platform that potentially enables strong anti-viral and anti-inflammatory properties to affect a new class of therapeutics.
Nano-C and Unify are in the process of negotiating a term sheet to pursue a strategic alliance. This strategic partnership marks Nano-C’s market expansion into biopharmaceuticals and gives Unify access to Nano-C’s leading-edge organic chemists for the optimization of UP-1007 and next generation APIs, and at the volumes and quality required during the clinical trial phase and into commercialization.
This press release is not a solicitation or offer to buy or sell securities. For illustrative purposes only. Investments may be speculative, illiquid and carry a risk of loss. Past performance is not indicative of future results. There is no guarantee that any specific outcome will be achieved.
About Nano-C, Inc. Nano-C is a leading innovator and manufacturer in the chemistry of nanostructured carbon, including fullerenes, carbon nanotubes (CNT), and their chemical derivatives. Nano-C is focused on fundamental technology trends: the roll-out of 5G, connectivity driven by the Internet of Things, the race to extend Moore’s Law, the move to address climate change through sustainable energy generation and now healthcare. Proprietary materials produced by Nano-C are critical links in the value chain for next-generation electronics, sensors, semiconductor manufacturing and biopharmaceuticals. Nano-C’s advanced materials and molecular platform encompasses a portfolio of unique solutions protected by over 150 global patents across 46 patent families. Through its patented products and processes, and its distinct competencies in the chemistry of these materials, Nano-C is enabling a revolution in device design, manufacture, and performance, and it is committed to their responsible development and use. For more information, please visit our website at www.nano-c.com. About Unify Pharmaceuticals Unify Pharmaceuticals is a biotech company utilizing the latest scientific discoveries to develop drugs targeting neurodegenerative diseases such as Parkinson’s Disease, Myocardial Infarction, Macular Degeneration, Alzheimer’s and Strokes. The company is the culmination of over 20 years’ research into UP-1007 and related molecules. UP-1007 is the first-in-class water-soluble fullerene that has been shown to successfully address the underlying causes of Parkinson’s and other diseases involving oxidative damage. For more information please visit www.unifypharma.com. About Boustead Securities, LLC Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com. About Sutter Securities Group, Inc. Headquartered in Irvine, California, Sutter Securities Group, Inc. (“SSG”), founded in 2013, through its affiliates, is an innovator and investment banking solutions provider. SSG owns and operates Sutter Securities Clearing, LLC, and Sutter Securities Incorporated, FINRA member broker-dealers; Sutter Shareholder Services, LLC, a SEC-registered transfer agent; FlashFunders Funding Portal, LLC, a FINRA member funding portal; and Sutter Capital Management, Inc. Sutter Securities Group, through its affiliates, operates a U.S.-based online securities platform whose underlying technology and regulatory infrastructure are designed to enable issuers to engage in Regulation D, Regulation A (known as Reg A+), Regulation S, Regulation CF and fully registered S-1 and F-1 Initial Public Offerings in compliance with applicable federal, state and non-U.S. securities laws. SSG is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. Additional information is available at www.flashfunders.com. Forward-Looking Statements This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.
